• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

    1/8/25 4:31:59 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sailer Carl

    (Last) (First) (Middle)
    C/O ACURX PHARMACEUTICALS, INC.,
    259 LIBERTY AVENUE

    (Street)
    STATEN ISLAND NY 10305

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Acurx Pharmaceuticals, Inc. [ ACXP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/06/2025 P 24,631(1) A $1.015 137,183 D
    Common Stock 5,000 I By Spouse
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants for Common Stock $0.9 01/06/2025 P 24,631(2) 01/07/2025 01/07/2030 Common Stock 24,631 $0 24,631 D
    Explanation of Responses:
    1. Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.
    2. Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.
    /s/ Kostantinos Skordalos, Power of Attorney For: Carl V. Sailer 01/08/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACXP

    DatePrice TargetRatingAnalyst
    11/29/2021$12.00Buy
    Maxim Group
    More analyst ratings

    $ACXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Acurx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/24 2:39:21 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:59:03 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Acurx Pharmaceuticals Inc.

      SC 13G - Acurx Pharmaceuticals, Inc. (0001736243) (Subject)

      2/14/23 11:52:45 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Financials

    Live finance-specific insights

    See more
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter and full year 2024 financial results on Tuesday, March 18, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, March 18, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-79

      2/28/25 8:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

      STATEN ISLAND, N.Y., Nov. 13, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2024. Highlights of the third quarter ended September 30, 2024, or in some cases shortly thereafter, include: In July 2024, results from the ibezapolstat (IBZ) Phase 2 clinical trial in patients with C. difficile Infection (CDI) were presented at the 17th Biennial Congress of the Anaerobe Society of the Americas by Taryn A. Eubank, PharmD, BCIDP,

      11/13/24 7:00:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

      STATEN ISLAND, N.Y., May 13, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the first quarter ended March 31, 2025.   Highlights of the first quarter ended March 31, 2025, or in some cases shortly thereafter, include: In January 2025, the Company announced it had closed a $2.5 million registered direct offering priced at the market under Nasdaq rules.Also in January 2025, we announced that we received positive regulatory guidance from the European Medicines Agency (E

      5/13/25 7:01:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

      STATEN ISLAND, N.Y., April 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2025 financial results on Tuesday, May 13, 2025 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Tuesday, May 13, 2025 Time: 8:00 a.m. ET Toll free (U.S.): 1-877-790-1503; Conference

      4/30/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

      STATEN ISLAND, N.Y., April 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals (NASDAQ:ACXP) (Acurx or the Company), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections today announced that David P. Luci, President & Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase on Wednesday, May 21, 2025, at 9:00 a.m. ET. The Company's lead antibiotic candidate, ibezapolstat (IBZ), is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection (CDI). A live webcast of the presentation can be found here. A replay o

      4/28/25 7:30:00 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Shawah Robert G.

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:47:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Luci David P

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:46:58 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Deluccia Robert J

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      2/6/25 5:45:47 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:32:30 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sailer Carl bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 22% to 137,183 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:59 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Luci David P bought $50,000 worth of shares (49,261 units at $1.01), increasing direct ownership by 5% to 1,097,458 units (SEC Form 4)

      4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

      1/8/25 4:31:33 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Acurx Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Acurx Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      11/29/21 8:33:36 AM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACXP
    SEC Filings

    See more
    • SEC Form S-1 filed by Acurx Pharmaceuticals Inc.

      S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/21/25 4:16:04 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Acurx Pharmaceuticals Inc.

      D - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/20/25 3:32:14 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Acurx Pharmaceuticals Inc.

      PRE 14A - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

      5/19/25 4:05:41 PM ET
      $ACXP
      Biotechnology: Pharmaceutical Preparations
      Health Care